Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zafirlukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 5/20 | 1.00 |
| ▸ | PLA2G4A | P47712 | 5/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 4/20 | 1.00 |
| ▸ | PPARG | P37231 | 4/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PTGES | O14684 | 1/20 | 1.00 |
| ▸ | XPO1 | O14980 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zafirlukast SCHEMBL6600322 | 1.00 | PLA2G4A (1.00) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL29861631 | 1.00 | PLA2G4A (1.00) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL29372773 | 1.00 | PLA2G4A (1.00) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL30885065 | 1.00 | PLA2G4A (1.00) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL6765680 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL4586973 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL8951202 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL6381072 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL6378803 | 0.99 | PLA2G4A (0.99) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 | |
| Zafirlukast SCHEMBL6715413 | 0.99 | PLA2G4A (0.97) | PLA2G4ACYSLTR1EPHX2PPARGCYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 24907 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436924-B1 | — | — | None | — | — | US | claimed |
| CN-122036587-A | Zalutst compound and application thereof in inhibiting MLL1-WDR5 interaction | 暨南大学 | 2026-05-15 | — | — | CN | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12569451-B2 | Bio-inspired tissue-adhesive hydrogel patch and uses thereof | Cellartgen Inc. (KR) | 2026-03-10 | — | — | US | claimed |
| EP-4699655-A2 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-02-25 | — | — | EP | claimed |
| US-12545948-B2 | Identification of novel loci in asthma and methods of use thereof for the diagnosis and treatment of asthma | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-02-10 | — | — | US | claimed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4676956-A2 | ANTI-STEM CELL FACTOR (SCF) AND ANTI-THYMIC STROMAL LYMPHOPOIETIN (TSLP) ANTIBODIES AND BISPECIFIC CONSTRUCTS | Celldex Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4678659-A1 | MONOCLONAL ANTIBODY PREPARATION TARGETING TSLP | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | claimed |
| US-20260007719-A1 | COMPOSITION FOR INTERMITTENT DOSING OF CALCINEURIN INHIBITORS | KLEE TREVOR (US) | 2026-01-08 | — | — | US | claimed |
| US-5482963-A | Physical form of N-(4-(5(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl -methyl)3methoxybenzoyl)-2-methylbenzenesulphonamide, zafirlukast; tablet; asthma | ZENECA LIMITED (GB) | 1996-01-09 | — | — | US | claimed |
| EP-0490648-B1 | Pharmaceutical agents | ZENECA LTD (GB) | 1995-12-06 | — | — | EP | claimed |
| EP-0469477-B1 | Antiallergic combination | HOFFMANN LA ROCHE (CH) | 1995-09-20 | — | — | EP | claimed |
| US-5319097-A | Physical form of leukotriene antagonist such as zafirlukast, N-(4-(5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl)-3-methoxybenzoyl)-2methylbenzenesulfonamide; spray drying in acetone | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-06-07 | — | — | US | claimed |
| US-5294636-A | Such as zafirlukast; leukotriene antagonist; metered dose inhalers | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-03-15 | — | — | US | claimed |
| EP-0490649-A1 | A physical form of N-[4-[5-(cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulfonamide, a process for its preparation and pharmaceutical compositions containing it | ZENECA LIMITED (GB) | 1992-06-17 | — | — | EP | claimed |
| EP-0490648-A1 | Pharmaceutical agents | ZENECA LIMITED (GB) | 1992-06-17 | — | — | EP | claimed |
| EP-0469477-A1 | Antiallergic combination | F. HOFFMANN-LA ROCHE AG (CH) | 1992-02-05 | — | — | EP | claimed |
| EP-0199543-B1 | HETEROCYCLIC AMIDE DERIVATIVES | ICI AMERICAS INC. (US) | 1991-12-04 | — | — | EP | claimed |
| US-4859692-A | Heterocyclic amide derivatives and pharmaceutical use | ICI AMERICAS INC. (US) | 1989-08-22 | — | — | US | claimed |